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ABSTRACT
The efficacy and safety of various modes of
medical treatment for primary hyperpara-
thyroidism (PHPT) in pregnancy is largely
unknown. This report describes two cases of
PHPT in pregnancy that were temporarily
treated with the calcimimetic cinacalcet. The
first case was diagnosed in the 31st week of
pregnancy. The patient was asymptomatic and
had an albumin-corrected total calcium level
(Cacorr) of 3.24 mmol/1. As serum calcium was
only mildly elevated it was decided to postpone
surgery to the postpartum period. Cinacalcet
was started immediately after delivery to pre-
vent a postpartum surge in serum calcium. The
second patient presented with hypertension and
symptomatic hypercalcemia (Cacorr 3.96 mmol/1)
in the 32" week of pregnancy. Surgery was
postponed because of suspected pheochromo-
cytoma. Treatment with a combination of cina-
calcet and calcitonin reduced serum Cacorr to 3.0
mmol/1. This report describes the monitoring of
mother and child, and explores the pros and
cons of the use of calcimimetics during preg-
nancy and puerperium.
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INTRODUCTION
The prevalence of primary hyperparathyroidism
(PHPT) in women of childbearing age is about 5
per 10,000'"3. A diagnosis of PHPT is notoriously
difficult during pregnancy because it rarely presents
with classical symptoms. Most often the symptoms
are non-specific and easily mistaken for common
pregnancy-related symptoms. In addition, the
pregnancy-induced fall in serum albumin reduces
the total serum calcium and tends to mask
hypercalcemia unless ionized calcium is measured.
These are probably the main reasons why PHPT is
rarely diagnosed during pregnancy. Since the first
case was reported in 1932, only about 200 cases
have been published in the medical literature4.
PHPT is typically a disease of middle-aged and
elderly women. It usually runs a relatively benign
clinical course and rarely needs immediate,
lifesaving interventions. In contrast, during preg-
nancy PHPT may have serious clinical implications
for mother and child5"8. It may lead to hyperemesis
gravidarum, pre-eclampsia, nephrolithiasis, recur-
rent urinary tract infections, pancreatitis, hyper-
calcemic crisis, intrauterine growth retardation,
miscarriage, stillbirth, preterm labor, neonatal
tetany and neonatal death4"8. Pregnancy may also
develop uneventfully but even in cases of mild
PHPT severe fetal/neonatal complications have
been reported. At present there are no evidence-
based parameters that reliably predict the outcome
of PHPT in pregnancy, but most experts suggest
that severe complications are less likely if the total
serum calcium remains below 3.0 mmol/1.
Because the outcome cannot be accurately
predicted, it is not surprising that the optimal
management of PHPT during pregnancy is un-
resolved. Most authors advocate parathyroidectomy
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(PTx) during pregnancy as the treatment of choice
in the second trimester7. The safety of surgery in
the first and third trimesters is debated because of
the associated risks for the fetus9. Experience with
medical treatment for PHPT in pregnancy is very
limited and poorly documented. In less than 20% of
reported cases were adequate details provided about
the medical interventions and outcome. So far, only
intravenous hydration with or without forced
diuresis, and intravenous or subcutaneous calci-
tonin have emerged as safe treatments10. Both will
lower serum calcium only temporarily, and addi-
tional treatment of the underlying cause will always
be needed to prevent recurrent hypercalcemia.
MgSC«4 may be used to increase urinary calcium
excretion11. Oral or intravenous phosphate is not
recommended because it may cause extensive intra-
and extravascular calcium phosphate deposits
which may lead to severe organ failure12. Bis-
phosphonates cross the placenta and have been
shown in some animal models to interfere with
normal endochondral bone development. They
should only be used in emergencies as a short-term
intervention to stabilize severe hypercalcemia prior
13 14to surgery ' .
Calcimimetics are effective in reducing serum
calcium in PHPT; however, their use in pregnancy
has not yet been reported15'16. To our knowledge,
this is the first report describing the effects of the
calcimimetic cinacalcet during pregnancy and
puerperium.
PATIENT 1
A 35 year-old pregnant women, G2P1, was
referred to the Department of Endocrinology
because of recently discovered mild primary hypo-
thyroidism: free T4 11 pmol/1 (normal range [NR]:
11-25 pmol/1), TSH 4.87 mU/1 (NR: 0.3-4.0 mU/1),
anti-TPO antibodies negative. Thyroid replacement
therapy was started and euthyroidism was soon
established with thyroxin at a dose of 50 μg once
per day. She had used multivitamins on a daily
basis since gastric banding for morbid obesity
5 years earlier. Additional blood tests were
performed in the 31st week of pregnancy to rule out
hypo- or hypervitaminosis. The results were com-
patible with PHPT: serum total calcium 3.06
mmol/1, albumin 29.5 g/1, albumin-corrected total
calcium level (Cacorr) 3.32 mmol/1, ionized calcium
(Ca2+) 1.60 mmol/1, phosphate 0.71 mmol/1,
parathyroid hormone (PTH) 6.1 pmol/1 (NR in non-
pregnant women: 1.6-6.9 pmol/1), 25-hydroxy-
vitamin D 41 nmol/1 (NR: 50-100 nmol/1), 1,25-
dihydroxy-vitamin D 269 pmol/1 (NR: 48-161
pmol/1), and urinary calcium excretion 25.1 mmol/
24 h. Five years previously, serum total calcium
and phosphate levels had been within the normal
range (Ca2+ 2.43 mmol/1, phosphate 0.89 mmol/1).
Ultrasonography of the neck revealed a right
inferior parathyroid adenoma of 0.9 χ 1.6 cm.
Abdominal ultrasonography of the kidneys was
normal.
The patient was hospitalized in the 32nd week of
pregnancy to monitor calcium and phosphate
metabolism. She was advised to maintain a fluid
intake of 4 liters per day to ensure high urinary
calcium excretion. Serum Ca2+ levels and urinary
calcium excretion remained stable during the first
week (Fig. 1). Fetal ultrasound showed normal fetal
development without growth retardation. In a
multidisciplinary discussion it was concluded that
PTx was not the option of choice in this phase of
pregnancy because of the associated risk of preterm
labor. It was decided to perform a preterm delivery
at 36 weeks, either by induction of labor or by
Cesarean section. At 36 weeks labor induction with
oxytocin i.v. and dinoprostone gel treatment was
not successful. Therefore, a Cesarean section was
carried out as planned. A healthy son was
delivered, body weight 3,390 g (>90* percentile),
height 52 cm, head circumference 35.5 cm, Apgar
score 8-9, umbilical cord serum Ca2+ 1.77 mmol/1.
i.e. 0.37 mmol/1 higher than that of the mother
(Fig. 1). Macroscopic and microscopic examination
of the placenta did not reveal any abnormalities.
At the time of delivery, the mother's serum Ca2+
of 1.40 mmol/1 was rather low. This was attributed
to extensive fluid infusion which had been neces-
sary to maintain blood pressure during the Cesarean
section. To prevent a rapid surge of serum calcium
in the postpartum period, cinacalcet 30 mg twice
per day was started immediately after delivery, in
combination with infusion of 0.9% NaCl at a rate
of 4 1/24 h. During the subsequent days Ca2+
gradually decreased, and 7 days after the Cesarean
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Fig. 1: Patient 1. Serum ionized calcium in mother and child during pregnancy and puerperium (0 = delivery).
section the mother was discharged. Serum Ca2+
stabilized between 1.30 and 1.40 mmol/1 on cina-
calcet. Six weeks after delivery a right inferior
parathyroid adenoma of 2 cm was removed, and
this completely normalized serum calcium.
The neonate
Immediately after delivery, the infant was trans-
ferred to the neonatal intensive care unit. Labora-
tory results from cord blood samples are
summarized in Table 1. The son's serum Ca2+ level
was 0.37 mmol/1 higher than that of his mother.
Serum phosphate was markedly higher in the
neonate, whereas serum PTH and PTH-related
protein (PTHrp) were suppressed. Serum calcitonin
was nearly 20-fold higher than in the mother. The
neonate's l,25-(OH)2-vitamin D was half the level
observed in the mother, whereas 25-OH-vitamin D
levels were comparable. Vitamin D binding protein
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TABLE 1
Laboratory results in mother and infant (Patient 1), just after Cesarean section
Mother Infant Normal range
Cacorr (mmol/I)
Ca2+ (mmol/I)
Albumin (g/l)
pH
Phosphate (mmol/1)
PTH (pmol/1)
PTHrp (pmol/1)
Calcitonin (pmol/1)
25-OH-Vitamin I)3 (nmol/I)
1,25-(OH)2- Vitamin D3 (pmol/1)
Vitamin D binding protein (μί>/πιΙ)
3.06
1.40
20.8
7.46
0.74
13.1
<0.3
0.7
48
362
431
3.45
1.77
23.8
7.38
1.83
0.3
<0.3
13.6
40
187
257
2.10-2.55
1.10-1.30
35-50
7.35-7.45
0.87-1.45
1.6-6.9
0-0.6
0-4.7
50-100
48-161
217-449
For abbreviations see text. Normal ranges refer to normal values in non-pregnant adults.
was in the low normal range in the neonate and in
the high normal range in the mother. Ionized
calcium decreased rapidly and two days after
delivery a level of 1.10 mmol/1 was reached.
Infusion of calcium and oral ingestion of loc-
calcidiol was started, but this did not prevent a
further decline of serum Ca2+ to 0.80 mmol/1.
Neonatal tetany did not occur. Six days after the
start of treatment a consistent rise in serum calcium
was achieved, ending with a Ca2+ level around 1.30
mmol/1. The child was discharged in good health on
day 15. After 2 months calcium and vitamin D
supplementation was stopped permanently.
PATIEiNT2
A 40 year-old female, G2PO, was hospitalized in
the 32nd week of pregnancy because of progressive
hypertension (180/110 mm Hg) not responding to
methyldopa. There was no evidence of pre-
eclampsia. Polyuria (10-12 liters daily) and poly-
dipsia was noted and this prompted further
evaluation. Laboratory results were compatible
with a diagnosis of severe ΡΠΡΤ: total calcium 3.57
mmol/1, albumin 24.6 g/l, Cacorr 3.96 7 mmol/1,
Ca2+ 1.98 mmol/1, phosphate 0.65 mmol/1, PTII
16.1 pmol/1, urinary calcium excretion 32.7 mmol/
24 h. Plasma glucose, creatinine, and sodium were
within the normal range. Ultrasonography of the
neck did not reveal a parathyroid adenoma. Because
of the combination of hypertension and PHPT a
MEN 2A syndrome could not be ruled out with
certainty and thus parathyroid surgery was post-
poned pending further analysis. Intravenous hydra-
tion with 0.9% NaCl, 6 liter/24 h, did not reduce
serum Ca2+. Calcitonin alone was considered
ineffective for the long-term Ca2+ control needed in
this case, and so we chose to start treatment with
cinacalcet 30 mg twice daily. The dose was rapidly
increased to 240 mg/day, within one week. This
resulted in a temporary reduction of maternal serum
Ca2+ after three days, but after one week of
treatment serum Ca2+ had increased to its original
level. Calcitonin was added, first at a dose of 200
μg subcutaneously, and then 100 μ% subcutaneously
every other day. The combined regimen reduced
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serum Ca to a stable level of around 1.50 mmol/1
(Fig. 2). After confirmation that urinary catechol-
amine excretion was normal, surgery was planned
for the 34th week. Cesarean section was performed
first, directly followed by a right parathyroid
adenomectomy in the same session. A cord blood
sample taken immediately after delivery showed
elevated neonatal serum Ca2+ as compared to the
mother, indicating that the physiological Ca2+
gradient between mother and child was maintained
during the use of cinacalcet (Table 2). Vitamin D
and calcium supplementation was started on the
second day when serum Ca2+ had decreased to 1.05
mmol/1. Neonatal tetany did not occur. Vitamin D
and calcium supplementation was stopped after 11
days.
DISCUSSION
This paper describes the use of cinacalcet in two
cases of PHPT in pregnancy. The first case is an
example of asymptomatic, mild hyperparathyroid-
ism diagnosed in the third trimester of pregnancy.
Decisions about when and how to intervene are
S
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Fig. 2: Patient 2. Effect of cinacalcet monotherapy, combination treatment with cinacalcet and calcitonin, and subsequent surgery
on maternal ionized calcium levels in the third trimester of pregnancy.
TABLE 2
Effects of cinacalcet and calcitonin treatment on neonatal calcium homeostasis (Patient 2)
Total calcium (mmol/1)
Ca2+ (mmol/1)
Albumin (g/l)
PTH (pmo!/l)
Phosphate (mmol/1)
Mother
3.01
1.67
22.9
32.5
1.38
Child
3.28
1.85
27.2
<1
2.52
Laboratory results of samples obtained immediately after delivery.
Normal ranges are shown in Table 1.
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difficult in cases like this because systematically
analyzed clinical data are not available to guide our
judgment. At present, we do not know exactly what
threshold level of serum calcium is associated with
increased risks of serious complications. As
demonstrated by this patient, pregnancy may
continue uneventfully in cases of mild ΡΠΡΤ;
however, this case also illustrates that even mild
maternal hypercalcemia can cause neonatal hypo-
calcemia and hypoparathyroidism.
Withholding calcium lowering treatment during
pregnancy may put the mother and fetus at risk for
more severe complications17. The use of cinacalcet
during pregnancy was discussed at length but
eventually rejected because of lack of safety data in
humans. Conservative management with watchful
waiting until full term was considered too
dangerous because any event associated with a
decline in renal function might compromise cal-
cium excretion and could thus precipitate a
hypercalcemic crisis. It was decided to provide
adequate hydration and plan a preterm delivery at
36 weeks to avoid the physiological decline in
maternal glomerular filtration rate (GFR) that
occurs in the late phase of pregnancy18. We also
started cinacalcet immediately after delivery to
prevent a rise in serum calcium that might occur as
a result of the loss of calcium shunting to the fetus,
the rapid decline in GFR that follows delivery, and
the onset of accelerated bone resorption with early
lactation. As shown in Figure 1, cinacalcet
gradually lowered serum Ca2+ to 1.36 mmol/1 in 2
weeks, and parathyroid surgery was safely post-
poned until the patient had recovered from the
Cesarean section.
The second case is, to our knowledge, the first
to demonstrate that the use of cinacalcet for PHPT
in pregnancy does not compromise fetal blood
calcium or apparent placental calcium transport. At
birth the neonatal Ca2+ level was 0.18 mmol/1
higher than in the mother (Table 2). This case also
illustrates that cinacalcet monotherapy is not useful
for the acute control of serum calcium in severe
PHPT (Fig. 2). To some extent this was expected
since at least 2 weeks of treatment of non-pregnant
patients with PHPT are required to reach the nadir
calcium levels for a given dose15. We hoped to
induce an earlier response by rapidly increasing the
dose up to its maximum. Unfortunately, only a
temporary decline was observed, and after one
week of treatment serum calcium was again at its
peak level. In contrast, the combination of cinacal-
cet and calcitonin proved highly effective in redu-
cing serum Ca2+ to our target level of 1.50 mmol/1.
We did not wish to normalize serum calcium
because too large a decline in serum calcium might
trigger premature labor or compromise fetal
calcium metabolism. Serum calcium was monitored
every 6 hours, and this permitted careful titration of
calcitonin. After an initial dose of 200 μg of
calcitonin, a dose of 100 μg every other day in
combination with cinacalcet was sufficient to
maintain serum calcium at the desired level. Mono-
therapy with calcitonin every other day would not
have achieved this consistent lowering in serum
calcium given the rapid tachyphylaxis that occurs in
response to calcitonin. We hypothesize that the
combination treatment prevents the PTH surges
that are likely to occur in response to the calcium
lowering effects of calcitonin monotherapy.
Before considering cinacalcet treatment we
extensively discussed the pros and cons because its
use in human pregnancy had not been previously
reported. Cinacalcet is a calcimimetic that activates
the calcium sensing receptor (CaSR) present on
parathyroid cells, C-cells of the thyroid, and renal
distal tubular cells. Activation of the CaSR reduces
PTH secretion and increases calcitonin release,
whereas activation of the renal tubular cell CaSR
reduces renal calcium resorption independently
of changes in PTH19. Cinacalcet has been used
successfully to treat PHPT in non-pregnant wo-
men15'16. The recommended starting dose is 30 mg
twice a day, and it may be increased to up to 180-
360 mg/day. It takes about 2 weeks before steady
state is reached on a given dose. Safety and efficacy
have not been established in patients below the age
of 18 years. Animal studies in pregnant rats and
rabbits have shown that cinacalcet crosses the
placenta; however, embryonal or fetal toxicity or
harmful effects with respect to pregnancy or
parturition have not been observed20. Based on
these data, cinacalcet has been classified as a
category C drug. Considering the demonstrated
efficacy of cinacalcet in non-pregnant women, there
is little doubt that cinacalcet will also lower serum
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calcium in pregnant women. It should thus reduce
the feto-maternal complications of hyperpara-
thyroidism that are due to the hypercalcemia.
However, there are two main concerns for its use in
pregnancy. First, effects on fetal calcium levels
have not been studied previously; secondly, direct
frequent monitoring of fetal calcium levels is not
feasible. CaSRs are present in the placenta, and
thus cinacalcet might alter placental function to
cause fetal hypocalcemia, for example by suppres-
sing fetal PTH secretion, placental PTHrp produc-
tion, or the production of other factors contributing
to active placental calcium transport17. On the other
hand, several lines of evidence suggest that the use
of cinacalcet is likely to be safe, as long as the
mother is not made hypocalcemic. In normal preg-
nancy, fetal ionized calcium is about 0.3 mmol/1
higher than in the mother, due to active transport of
calcium across the placenta17. These high fetal
calcium levels suppress fetal parathyroid activity,
and fetal PTH levels are normally low or even
undetectable. In cases of maternal PHPT fetal
calcium levels are even higher and this will
completely suppress fetal PTH secretion. Thus, it is
very unlikely that cinacalcet would adversely affect
fetal parathyroid activity during PHPT in preg-
nancy, simply because fetal PTH production would
already be maximally suppressed in response to the
maternal hypercalcemia.
Potential adverse effects of cinacalcet on
placental active calcium transport are more difficult
to predict. To some extent, the safety of CaSR
modulation in humans can be deduced from an
experiment of nature, i.e. a gain-of-function
mutation of the CaSR. In affected children the
CaSR is overly sensitive to the effects of calcium to
such a degree that even subnormal calcium levels
can suppress PTH secretion and renal tubular
calcium resorption. This results in a clinical syn-
drome known as autosomal dominant hypocalcemia
(ADH), which is characterized by hypocalcemia
and hypercalciuria21"30. Most affected individuals
are detected during childhood or later in life
because of muscle spasms or seizures. A large
group is asymptomatic and only detected during
family survey, and only a very small number
present with tetany in the neonatal period. Table 3
summarizes all reported cases of ADH presenting
with neonatal tetany or with known calcium levels
in the neonatal period. All cases had an uneventful
pregnancy and delivery, even those from affected
mothers. None presented with hypocalcemic sei-
zures on the first day of life. The earliest sympto-
matic infant had seizures at 3 days of age26. This
relatively late onset of symptomatic hypocalcemia
suggests that calcium levels are likely to have been
normal at birth and imply that fetal calcium
homeostasis is not adversely affected by an increase
in CaSR sensitivity. Even in affected mothers with
serum total calcium levels between 1.63 and 1.75
mmol/1 the placental calcium pump must have been
functioning quite well as neonatal tetany occurred
as late as 6-7 days after birth. Apparently, the
placental CaSR is not pivotal in the regulation of
placental calcium transport.
Adverse effects of cinacalcet on neonatal cal-
cium homeostasis are also unlikely. As cinacalcet
has a half life of about 30 hours its effect will be
negligible after 3 days. A clinically significant
lengthening of the neonatal hypocalcemic period is
thus unlikely. The use of cinacalcet could con-
ceivably reduce the neonatal hypocalcemic period,
because lowering the maternal serum calcium
toward normal may lead to an increase in fetal PTH
from the typically undetectable levels associated
with maternal hypercalcemia. By reducing the
suppressive effects of maternal hypercalcemia on
fetal parathyroid development, this may speed up
the recovery of normal parathyroid function in the
neonatal period. The events in the neonate of
Patient 2 support this line of thought.
In conclusion, this report indicates that the
combination of cinacalcet and calcitonin may be an
effective approach to treat selected cases of PHPT
in the third trimester of pregnancy before surgery
can be safely performed. Clearly, additional studies
are needed to determine this treatment's relative
benefits and safety issues with respect to the mother
and fetus/neonate. Due to cinacalcet's delayed
onset of action, monotherapy is not useful for the
rapid correction of severe PHPT in pregnancy
unless combined with calcitonin. However, cinacal-
cet monotherapy may prove useful for mild PHPT
in the third trimester of pregnancy to postpone
surgery and avoid preterm labor or to prevent
severe neonatal hypoparathyroidism.
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TABLE 3
Timing of onset of symptoms and biochemical characteristics at the onset of symptoms in newborns with
a gain-of-function mutation of the calcium sensing receptor (CaSR) of affected and unaffected mothers
Genetics
A
A
A
A
A
A
A
A
B
B
C
C
C
C
C
C
Pregnancy
uneventful
NR
NR
NR
NR
uneventful
uneventful
NR
NR
uneventful
uneventful
uneventful
uneventful
twin
twin
uneventful
Delivery
38 wk
NR
NR
NR
NR
term
37 wk
NR
NR
term
term
38 wk
37 wk
34 wk
34 wk
37 wk
First symptoms
6 days
7 days
5 years
'asymptomatic at birth'
'asymptomatic at birth'
7 months
7 days
3 years
'shortly after birth'
3 days
24 days
5 days
21 days
7 days
8 days
1 4 days
Calcium M/N*
1.58/1.23
1.58/1.48
1.63/1.78
1.63/1.78
1.63/1.85
1.50/1.65
1.75/1.30
1.75/1.75
NL/1.76
NL/1.45
NL/1.10
NL/1.30
NL/1.54
NL/1.25
NL/0.99
NL/1.70
Reference
21
21
22
22
22
23
24
24
25
26
27
27
28
29
29
30
Genetics: A = mother and child affected; B = mother not affected, only father and child affected; C = child affected due to
de novo mutation.
NR = not reported; NL = normal.
* Serum total calcium in mother (M) and neonate (N) at the time of diagnosis in mmol/1.
The authors declare no conflict of interest.
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